Simple Summary Bladder cancer is the ninth most common cancer worldwide. Immune
checkpoint inhibitors, a novel class of immunotherapy drugs that restore natural antitumoral …

Introduction Several programmed death ligand-1 (PD1/L1) immune checkpoint inhibitors
(ICIs) are approved in urothelial carcinoma (UC). Patients and Methods To address the need …

The DNA damage response (DDR) pathway regulates DNA repair and cell survival, and
inactivating mutations in DDR genes can increase tumour mutational burden (TMB), a …

Abstract Objective To identify CD8+ T cell-related molecular clusters and establish a novel
gene signature for predicting the prognosis and efficacy of immunotherapy in bladder cancer …

Cisplatin-based chemotherapy has been the standard of care in metastatic urothelial cancer
(mUC) for more than two decades. However, many patients with comorbidities cannot …

Background As a general female malignant tumor, Uterine Corpus Endometrial Carcinoma
(UCEC) has high mortality and relapses. Cuproptosis was found to play an essential role in …

Metastatic upper tract urothelial carcinoma (mUTUC) has a poor prognosis. Immune
checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with metastatic urothelial …

Bladder cancer is the ninth most common cancer worldwide. Over 75% of non-muscle
invasive cancer patients require conservative local treatment, while the remaining 25% of …

Background The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-
PB™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in …

Preclinical modelling is a crucial component of advancing the understanding of cancer
biology and therapeutic development. Several models exist for understanding the …